Frequency of non-alcoholic fatty liver disease in a series of forensic cases in Mexico
DOI:
https://doi.org/10.19136/hs.a20n2.3839Abstract
The Mexican population is overweight (34%) and obese (21%). Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD). Most studies of the frequency and prevalence of NAFLD have been performed using ultrasonography. In Mexico, ultrasound-based studies have shown a prevalence of NAFLD of 15.7 to 17 %. Objective. The objective was to determine the frequency of NAFLD in apparently asymptomatic individuals who died instantly in a traffic accident and with not known background of liver disease. Material and Methods. Autopsies were performed at the Coroner’s Office in the Municipality of Boca del Río, Mexico, during the period from January to December 2016. The variables studied included age, sex, weight, height, abdominal perimeter, fat panicle-thickness, main cause of death, and liver biopsy (NASH CRN classification). Results. Of the 32 cases studied, 78.1 % were males. Average age was 48 years (range 20-80 years). The body mass index range (BMI) was 17-33. A 34% of cases had NAFLD. 27.3 % of the cases with NAFLD had a normal BMI. Conclusions. This postmortem study showed a higher frequency of asymptomatic hepatic steatosis than previously reported in the Mexican population. The establishment of timely national measures to detect and prevent complications of NFALD is necessary.Downloads
Metrics
References
Lizardi-Cervera J, Becerra LI, Chávez-Tapia NC, Ramos OME, Uribe EM. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. Rev Gastroenterol Mex 2006; 71 (4): 453-459.
https://pubmed.ncbi.nlm.nih.gov/23369462/
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15(1):11–20. doi: 10.1038/nrgastro.2017.109. https://pubmed.ncbi.nlm.nih.gov/28930295/
Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol. 2019. doi: 10.3350/cmh.2019.0065. https://pubmed.ncbi.nlm.nih.gov/31679316/
Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-568. doi: 10.1136/gutjnl-2019-318813. https://pubmed.ncbi.nlm.nih.gov/31366455/
Estes, C, Anstee QM, Arias-Loste MT. Bantel H. Bellentani S. Caballeria J. Colombo M, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol 2018; 69, 896–904. https://pubmed.ncbi.nlm.nih.gov/29886156/
Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors and workup. Clin Liver Dis (Hoboken). 2012;1 (4): 99-103. doi: 10.1002/cld.81. https://pubmed.ncbi.nlm.nih.gov/31186860/
Thomas EL, Hamilton G, Patel N, O'Dwyer R, Doré CJ, Goldin RD, Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-127. https://pubmed.ncbi.nlm.nih.gov/15591516/
Gonçalves LB, Miot HA, Domingues MAC, et al. Autopsy Patients With Obesity or Metabolic Syndrome as Basic Cause of Death: Are There Pathological Differences Between These Groups? Clin Med Insights Pathol. 2018; 11:1-7. doi: 10.1177/1179555718791575. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066805/
Sibulesky L. Normal liver anatomy. Clinical Liver Disease 2013; 2 (Suppl) (S1-S3) doi: 10.1002/cld.124. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/cld.124
Verdelho-Machado M, Cortéz-Pinto H. Fatty liver in lean patients: is it a different disease? Annals of Gastroenterology 2012; 25 (1): 1-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959355/
Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018; 68 (2): 268-279. doi: 10.1016/j.jhep.2017.09.003. https://pubmed.ncbi.nlm.nih.gov/29122391/
Maglio C, Pirazzia C, Pujia A, Valenti L, Romeo S. The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. Food Research International 2014; 63, Part B: 239-243. https://www.sciencedirect.com/science/article/pii/S0963996914000611
León-Mimila P, Vega-Badillo J, Gutiérrez-Vidal R, Villamil-Ramírez H, Villareal-Molina T, Larrieta-Carrasco E, López-Contreras BE, Kauffer LR. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity. Exp Mol Pathol. 2015; 98(2): 178-83. doi:10.1016/j.yexmp.2015.01.012. https://pubmed.ncbi.nlm.nih.gov/25597287/
Jafarian A, Ebrahimi A, Azmoudeh Ardalan F, Dashti H, Rahimi M, Salehi M, Toosi MN. NAFLD Prevalence in a Young Cadaveric Organ Donor Population. Hepat Mon. 2014; 14(10): e21574. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238153/
Roesch-Dietlen F, Dorantes-Cuéllar A, Carrillo-Toledo MG, Martínez-Sibaja C, Rojas-Carrera S, Bonilla-Rojas S, Uchino-Higueras V, Lagunas L, Carrasco-Arróniz MA, Soler-Leal B, León-Valdivieso J, Cid-Juárez S, Martínez JA. Frecuencia del hígado graso no alcohólico en un grupo de pacientes con síndrome metabólico estudiado en la Ciudad de Veracruz. Rev Gastroenterol Mex. 2006; 71(4): 446-452.
https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=14139
Lizardi-Cervera J, Laparra DI, Chávez-Tapia NC, Ostos ME, Esquivel MU.
Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects.
Rev Gastroenterol Mex. 2006; 71(4): 453-9.
Takata T, Sakasai-Sakai A, Takino JI, Takeuchi M. Evidence for Toxic Advanced Glycation End-Products Generated in the Normal Rat Liver. Nutrients. 2019;11(7). pii: E1612. doi: 10.3390/nu11071612. https:%2
